Navigation Links
arGEN-X Initiates Phase IbStudy of ARGX-111 in Cancer
Date:9/17/2013

, including complex receptors and highly conserved targets often intractable with other antibody technologies. SIMPLE Antibody™ generated leads are further differentiated as products through enhancement of cell killing properties (POTELLIGENT®, licensed from BioWa Inc.) and optimization of circulation time and distribution in the body (NHance™). ArGEN-X is also developing ABDEG™ technology, to potentiate the clearance of disease-causing autoantibodies.

In January 2013, arGEN-X initiated a Phase Ib clinical trial for ARGX-110, its most advanced SIMPLE Antibody™ program modulating CD70 via a unique mode of action in hematological and virally-induced solid tumors. A second CTA for ARGX-111, a novel anti-c-Met antibody to treat diverse solid tumors, is the subject of this press release.

The SIMPLE Antibody™ platform is covered by broad patent claims, enjoys an independent, unencumbered patent position and is free of target gatekeeping restrictions.

SIMPLE stands for Superior Immunodiversity with Minimal Protein Lead Engineering.

arGEN-X™, SIMPLE Antibody™ and NHance™ are deposited trademarks of arGEN-X BV.

For further information, please contact:

Citigate Dewe Rogerson
David Dible
Mark Swallow
Nina Enegren
T: +44(0)207-282-2949/2948/1050
E: david.dible@citigatedr.co.uk

arGEN-X
Tim Van Hauwermeiren, MSc, eMBA
Chief Executive Officer
T: +31-6-122-85-257
E: tim.vh@arGEN-X.com

Alain Thibault, M.D.
Chief Medical Officer
T: +32-471-81-71-24
E: athibault@argen-x.com



'/>"/>
SOURCE arGEN-X
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. arGEN-X Appoints Dr. David L. Lacey to its Supervisory Board
2. arGEN-X Announces Preclinical Development of ARGX-112 for Dermatology
3. arGEN-X Identifies Potent Antibody Antagonists against Complex Chronic Pain Target Nav1.7
4. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
5. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
6. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
7. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
8. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
9. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
10. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
11. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ... Consumables Market - Global Industry Analysis, Size, Share, Growth, ... their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... are used on patients in order to treat dental ...
(Date:1/15/2014)... LAWRENCEVILLE, N.J. , Jan. 15, 2014  Celsion Corporation (the ... it has received commitments from institutional investors to purchase ... common stock in an at-the-market registered direct offering, led ... Company entered into definitive purchase agreements with these investors ...
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... Pharmaceuticals, Inc. (NASDAQ: ARNA ) today reported ... 2011. "We are focused on submitting our ... letter around year-end and filing the lorcaserin marketing authorization ... half of next year," stated Jack Lief, Arena,s President ...
... Nov. 9, 2011 Jay Yadav, M.D. , ... of the Year Award by the Association of Telecom ... medical device company that has developed and is commercializing ... human body. Dr. Yadav won the award in the ...
Cached Medicine Technology:Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 2Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 3Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 4Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 5Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 6Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 7Arena Pharmaceuticals Announces Third Quarter 2011 Financial Results 8The Association of Telecom Professionals Selects Dr. Jay Yadav, CardioMEMS Founder & CEO, as an Atlanta Telecom Professional of the Year in the Industry Innovation Category 2The Association of Telecom Professionals Selects Dr. Jay Yadav, CardioMEMS Founder & CEO, as an Atlanta Telecom Professional of the Year in the Industry Innovation Category 3
(Date:4/18/2014)... online in The Gerontologist reports ... associated with a decrease in anxiety about death and ... over their lives. In particular, listening to gospel music ... and an increase in sense of control. , These ... men, and individuals of both low- and high-socioeconomic status. ...
(Date:4/18/2014)... made a brain-related discovery that could revolutionize doctors, ... discovery opens up the possibility that environmental and/or ... brain activity that the researchers have identified as ... of Neuroscience has just published a paper ... professor of psychology and his doctoral student John ...
(Date:4/17/2014)... who show signs of chronic inflammation in non-cancerous prostate ... having prostate cancer than those with no inflammation, according ... from the Johns Hopkins Kimmel Cancer Center. , The ... for men with so-called high-grade prostate cancer those ... indicating the presence of the most aggressive and rapidly ...
(Date:4/17/2014)... Biology and Medicine a multidisciplinary research team ... in the Institute of Genomic Biology (IGB) on ... describe their recent work on subcellular redox homeostasis. ... functions including energy metabolism, signaling, and transcriptional processes. ... cellular behavior, redox status has been recognized as ...
(Date:4/17/2014)... biology team has created a new technology for ... could travel the body and selectively target cancer ... biological devices that monitor and modify human physiology ... However, no existing technology enabled bioengineers to build ... and respond in a customized fashion. , "The ...
Breaking Medicine News(10 mins):Health News:Religious music brings benefit to seniors' mental health 2Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 2Health News:Chronic inflammation linked to 'high-grade' prostate cancer 3Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:Building 'smart' cell-based therapies 2
... healthcare communities throughout ... ... of,Health IT Conference and Exhibition in Copenhagen, Microsoft Corp. and the,Healthcare ... Health Users Group (Microsoft HUG) across,Europe, the Middle East and Africa ...
... 4 Kaiser Foundation Health Plan,Inc., Kaiser Foundation ... of $10.2 billion for the quarter ended September,30, ... period last year., KFHP/H,s operating income in ... million in the same quarter last year. Financial ...
... Calif., Nov. 4 XTENT, Inc.,(Nasdaq: XTNT ) today ... September 30, 2008., The company reported a net loss ... of 2008, compared to a net loss of $9.5 million, ... the nine months ended,September 30, 2008, XTENT had a net ...
... (Nasdaq: WHRTD ) --,World Heart Corporation (the ... had received a NASDAQ Staff Deficiency Letter indicating ... 4310(c)(7). This rule,requires the Company to maintain a ... on the NASDAQ Capital Market. For purposes of ...
... VION,PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced updated ... 2008 to,discuss its 2008 third quarter financial results., ... To participate in the conference call, please dial ... at least 15 minutes,before the start of the call. ...
... N.Y. -- Researchers at the University at Buffalo have ... in utero to develop obesity in adulthood. , Moreover, ... metabolic programming occurs in the fetal hypothalamus, the area ... homeostasis (body weight) throughout life. , Levels of the ...
Cached Medicine News:Health News:Microsoft and HIMSS Launch Health Users Group Across EMEA 2Health News:Microsoft and HIMSS Launch Health Users Group Across EMEA 3Health News:Kaiser Foundation Health Plan and Hospitals Report Third Quarter Results 2Health News:Kaiser Foundation Health Plan and Hospitals Report Third Quarter Results 3Health News:Kaiser Foundation Health Plan and Hospitals Report Third Quarter Results 4Health News:XTENT Announces Third Quarter 2008 Financial Results 2Health News:XTENT Announces Third Quarter 2008 Financial Results 3Health News:XTENT Announces Third Quarter 2008 Financial Results 4Health News:WorldHeart Receives Notice From the NASDAQ Stock Market Regarding Non-Compliance With Marketplace Rule 4310(c)(7) 2Health News:Vion Updates Conference Call Information 2Health News:Vion Updates Conference Call Information 3Health News:Maternal obesity can program fetal brain to induce adult-onset obesity 2
Inquire...
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Single-action scissors offer fine-pointed, sharp dissecting jaws to facilitate a partial cut in the cystic duct in preparation for a cholangiogram. They are tapered at the tip for greater visualizati...
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
Medicine Products: